14 results on '"Liu, Kan"'
Search Results
2. Intraoperative radiotherapy (IORT) versus whole-breast external beam radiotherapy (EBRT) in early stage breast cancer: results from SEER database
- Author
-
Lei, Juan, Wang, Yi, Bi, Zhuofei, Xue, Shengneng, Ou, Bing, and Liu, Kan
- Published
- 2020
- Full Text
- View/download PDF
3. Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
- Author
-
Xu, Yongkang, Fu, Shumin, Liu, Kan, Mao, Ye, and Wu, Jianbing
- Subjects
SORAFENIB ,REGORAFENIB ,PROGRAMMED cell death 1 receptors ,PROGNOSIS ,SURVIVAL rate ,TREATMENT failure ,SURVIVAL analysis (Biometry) - Abstract
Purpose: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure.Methods: From June 2018 to September 2021, 68 patients from a single center who received lenvatinib combined with PD-1 inhibitors or regorafenib after sorafenib treatment failure were analyzed. The tumor response and survival outcomes were compared between the LP group and R group. Prognostic factors for OS and PFS were determined using Cox proportional hazard regression models.Results: The ORR increased in the LP group (19.5% vs 7.4%, p =0.294), and the DCR was better in the R group (73.2% vs 44.4%, p =0.017). Additionally, median PFS and OS were not significantly different between the LP group and R two groups in survival analysis (PFS: 5.3 months vs 3.0 months, p =0.633; OS: 11.8 months vs 8.0 months, p =0.699). The common adverse events (≥grade 3) were hand-foot skin reactions (13.1%). In multivariate analyses, AFP≥ 400 ng/mL and ECOG PS 2 were independent risk factors for poor prognosis.Conclusion: The LP group appeared to have a trend of greater tumor response and a higher disease control rate than the R group among patients with sorafenib-resistant HCC, although PFS and OS did not differ significantly between the two groups. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.
- Author
-
Li, Dan, Huang, Shenglan, Luo, Chen, Xu, Yongkang, Fu, Shumin, Liu, Kan, and Wu, Jianbing
- Subjects
CHEMOKINES ,LIVER cancer ,NUCLEOTIDE sequence ,PROGRESSION-free survival ,POLYMERASE chain reaction ,BIOLOGICAL tags - Abstract
The Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing (CMTM) family, comprising nine members, is involved in the tumorigenesis and progression of various cancers. However, the expression profiles and clinical significance of CMTM family members in hepatocellular carcinoma (HCC) are not fully clarified. In this study, the RNA-sequencing and clinical data were downloaded from The Cancer Genome Atlas (TCGA) databases. The Kaplan–Meier method and the Cox proportional hazards regression analysis were used to evaluate the prognostic significance of CMTM family members. Single-sample gene set enrichment analysis (ssGSEA) and ESTIMATE algorithms were employed to explore the relationship between CMTM family genes and the tumor microenvironment in HCC. Finally, the prognostic CMTM family gene expression was further validated by quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemical (IHC) staining in clinical HCC tissue specimens. The results indicated that, compared with normal tissues, the expression of CKLF, CMTM1, CMTM3, CMTM4, CMTM7, and CMTM8 were significantly upregulated in HCC, while the expression of CMTM2, CMTM5, and CMTM6 were significantly downregulated in HCC. Univariate and multivariate Cox regression analysis demonstrated that CKLF was an independent prognostic biomarker for the overall survival (OS) of HCC patients. In HCC, the expression of CKLF was found to be correlated with immune cell infiltration, immune-related functions, and immune checkpoint genes. The qRT-PCR and IHC confirmed that CKLF was highly expressed in HCC. Overall, this research suggested that CKLF is involved in immune cell infiltration and may serve as a critical prognostic biomarker, which provides new light on the therapeutics for HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2
- Author
-
Sun, ZhiFeng, Zhang, Zhang, Liu, Zidong, Qiu, Bo, Liu, Kan, and Dong, Guanglong
- Published
- 2014
- Full Text
- View/download PDF
6. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
- Author
-
Liu, Kan, Wu, Jianbing, Xu, Yongkang, Li, Dan, Huang, Shenlang, and Mao, Ye
- Subjects
- *
HEPATOCELLULAR carcinoma , *SORAFENIB , *PROGRAMMED cell death 1 receptors , *REGORAFENIB , *ALPHA fetoproteins , *PROGNOSIS , *DRUG efficacy - Abstract
Background: Regorafenib is the first oral targeted drug as a second-line agent in patients with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib treatment. Recently, several studies demonstrated that the combination of regorafenib and PD-1 inhibitors showed a synergistic effect. Our study aimed to evaluate the efficacy of regorafenib with PD-1 inhibitors (RP) and regorafenib alone (R) as second-line treatment for advanced HCC. Methods: From October 2018 to January 2022, our retrospective study evaluated advanced HCC patients who received regorafenib with PD-1 inhibitors or regorafenib alone as a second-line treatment at the Second Affiliated Hospital of Nanchang University, China. The efficacy and safety were compared between RP and R groups. Results: In total, 78 patients were enrolled in our study and were separated into two groups – RP group (48) and R group (30) – according to the criteria. The ORR of RP group and R group was 18.8% and 10%, respectively, and the DCR was 66.7% and 43.3%, respectively. The RP group had a longer mPFS (5.9 months vs 3.0 months, P< 0.001) and mOS (12.9 months vs 10.3 months, P=0.010) than the R group. Regorafenib monotherapy is an independent prognostic factor for OS and PFS. In OS, subgroup analysis showed that patients with AFP ≥ 400ng/mL, BCLC C stage and extrahepatic metastasis may benefit from RP, while in PFS, subgroup analysis showed that patients with BCLC C stage, AFP ≥ 400ng/mL, extrahepatic metastasis, ALBI ≥-2.60 and first-line treatment of sorafenib may benefit from RP. The incidence of grade 3/4 adverse reaction in the two groups was 22.9% and 23.3%, respectively, with no significant statistically difference (P=0.966). Conclusion: In the second-line therapy of advanced HCC, compared to regorafenib alone, the combination of regorafenib and PD-1 inhibitors showed promising efficacy and tolerable drug toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome
- Author
-
Cammann, Victoria L, Scheitz, Jan F., Ghadri, Jelena R, Budnik, Monika, Opolski, Grzegorz, Borggrefe, Martin, Thiele, Holger, Bauersachs, Johann, Katus, Hugo A, Horowitz, John D, Di Mario, Carlo, Münzel, Thomas, Crea, Filippo, Consortium, InterTAK, Bax, Jeroen J, Scherff, Frank, Niederseer, David, Lüscher, Thomas F, Citro, Rodolfo, Vecchione, Carmine, Bossone, Eduardo, Gili, Sebastiano, Neuhaus, Michael, Franke, Jennifer, Meder, Benjamin, Jaguszewski, Miłosz, von Rennenberg, Regina, Noutsias, Michel, Knorr, Maike, Jansen, Thomas, D'Ascenzo, Fabrizio, Dichtl, Wolfgang, Burgdorf, Christof, Kherad, Behrouz, Tschöpe, Carsten, Sarcon, Annahita, Shinbane, Jerold, Jäncke, Lutz, Rajan, Lawrence, Michels, Guido, Pfister, Roman, Cuneo, Alessandro, Jacobshagen, Claudius, Karakas, Mahir, Koenig, Wolfgang, Pott, Alexander, Meyer, Philippe, Roffi, Marco, Nolte, Christian, Banning, Adrian, Wolfrum, Mathias, Cuculi, Florim, Kobza, Richard, Fischer, Thomas, Vasankari, Tuija, Airaksinen, K E Juhani, Napp, L Christian, Dworakowski, Rafal, MacCarthy, Philip, Szawan, Konrad A, Kaiser, Christoph, Osswald, Stefan, Galiuto, Leonarda, Chan, Christina, Bridgman, Paul, Beug, Daniel, Delmas, Clément, Lairez, Olivier, Gilyarova, Ekaterina, Shilova, Alexandra, Stengl, Helena, Gilyarov, Mikhail, El-Battrawy, Ibrahim, Akin, Ibrahim, Poledniková, Karolina, Toušek, Petr, Winchester, David E, Galuszka, Jan, Ukena, Christian, Poglajen, Gregor, Carrilho-Ferreira, Pedro, Würdinger, Michael, Hauck, Christian, Paolini, Carla, Bilato, Claudio, Kobayashi, Yoshio, Kato, Ken, Shoji, Toshihiro, Ishibashi, Iwao, Takahara, Masayuki, Himi, Toshiharu, Din, Jehangir, Endres, Matthias, Al-Shammari, Ali, Prasad, Abhiram, Rihal, Charanjit S, Liu, Kan, Schulze, Peter, Bianco, Matteo, Jörg, Lucas, Rickli, Hans, Pestana, Gonçalo, Nguyen, Thanh H, Templin, Christian, Böhm, Michael, Maier, Lars S, Pinto, Fausto J, Widimský, Petr, Felix, Stephan B, Braun-Dullaeus, Ruediger C, Rottbauer, Wolfgang, Hasenfuß, Gerd, Pieske, Burkert M, Schunkert, Heribert, University of Zurich, and Repositório da Universidade de Lisboa
- Subjects
Adult ,Male ,Science ,Cardiology ,heart disease risk factors ,complications [Seizures] ,Article ,Seizures ,Takotsubo Cardiomyopathy ,diagnosis [Takotsubo Cardiomyopathy] ,Humans ,Hospital Mortality ,Registries ,humans ,Ischemic Stroke ,Aged ,Aged, 80 and over ,hospital mortality ,mortality [Takotsubo Cardiomyopathy] ,Multidisciplinary ,complications [Intracranial Hemorrhages] ,10093 Institute of Psychology ,etiology [Takotsubo Cardiomyopathy] ,Middle Aged ,Prognosis ,complications [Ischemic Stroke] ,Outcomes research ,Heart Disease Risk Factors ,10209 Clinic for Cardiology ,Medicine ,Female ,150 Psychology ,Intracranial Hemorrhages ,ddc:600 - Abstract
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., Cardiac alterations are frequently observed after acute neurological disorders. Takotsubo syndrome (TTS) represents an acute heart failure syndrome and is increasingly recognized as part of the spectrum of cardiac complications observed after neurological disorders. A systematic investigation of TTS patients with neurological disorders has not been conducted yet. The aim of the study was to expand insights regarding neurological disease entities triggering TTS and to investigate the clinical profile and outcomes of TTS patients after primary neurological disorders. The International Takotsubo Registry is an observational multicenter collaborative effort of 45 centers in 14 countries (ClinicalTrials.gov, identifier NCT01947621). All patients in the registry fulfilled International Takotsubo Diagnostic Criteria. For the present study, patients were included if complete information on acute neurological disorders were available. 2402 patients in whom complete information on acute neurological status were available were analyzed. In 161 patients (6.7%) an acute neurological disorder was identified as the preceding triggering factor. The most common neurological disorders were seizures, intracranial hemorrhage, and ischemic stroke. Time from neurological symptoms to TTS diagnosis was ≤ 2 days in 87.3% of cases. TTS patients with neurological disorders were younger, had a lower female predominance, fewer cardiac symptoms, lower left ventricular ejection fraction, and higher levels of cardiac biomarkers. TTS patients with neurological disorders had a 3.2-fold increased odds of in-hospital mortality compared to TTS patients without neurological disorders. In this large-scale study, 1 out of 15 TTS patients had an acute neurological condition as the underlying triggering factor. Our data emphasize that a wide spectrum of neurological diseases ranging from benign to life-threatening encompass TTS. The high rates of adverse events highlight the need for clinical awareness., The International Takotsubo Registry was supported by the Biss Davies Charitable Trust. Dr. Scheitz has been supported by the Corona Foundation. Dr. Templin has been supported by the H.H. Sheikh Khalifa bin Hamad Al-Thani Research Programme and the Swiss Heart Foundation.
- Published
- 2021
8. A Risk Signature with Autophagy-Related Long Noncoding RNAs for Predicting the Prognosis of Clear Cell Renal Cell Carcinoma: Based on the TCGA Database and Bioinformatics.
- Author
-
Xuan, Yundong, Chen, Weihao, Liu, Kan, Gao, Yu, Zuo, Shidong, Wang, Baojun, Ma, Xin, and Zhang, Xu
- Subjects
RENAL cell carcinoma ,NON-coding RNA ,LINCRNA ,REGRESSION analysis ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,BIOINFORMATICS - Abstract
Background. Disorders of autophagic processes have been reported to affect the survival outcome of clear cell renal cell carcinoma (ccRCC) patients. The purpose of our study was to identify and validate the candidate prognostic long noncoding RNA signature of autophagy. Methods. Transcriptome profiles were obtained from The Cancer Genome Atlas. The autophagy gene list was obtained from the Human Autophagy Database. Based on coexpression analysis, we obtained a list of autophagy-related lncRNAs (ARlncRNAs). GO enrichment analysis and KEGG pathway analysis were conducted to explore the functional annotation of these ARlncRNAs. Univariate and multivariate Cox regression analyses were conducted to elucidate the correlation between overall survival and the expression level of each ARlncRNAs. We then established a prognostic signature that was a linear combination of the regression coefficients from the multivariate Cox regression model (β) multiplied by the expression levels of the respective ARlncRNAs in the training cohort. The predictive performance was tested in the validation cohort. Additionally, the independence of the risk signature was assessed, and the relationship between the risk signature and conventional clinicopathological features was explored. Results. Seven autophagy-related lncRNAs with prognostic value (SNHG3, SNHG17, MELTF-AS1, HOTAIRM1, EPB41L4A-DT, AP003352.1, and AC145423.2) were identified and integrated into a risk signature, dividing patients into low-risk and high-risk groups. The risk signature was independent of conventional clinical characteristics as a prognostic indicator of ccRCC (HR, 1.074, 95% confidence interval: 1.036-1.113, p < 0.001) and was valuable in the prediction of ccRCC progression. Conclusion. Our risk signature has potential prognostic value in ccRCC, and these ARlncRNAs may play a significant role in ccRCC tumor biology. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Regional Myocardial Remodeling Characteristics Correlates With Cardiac Events in Sarcoidosis.
- Author
-
Lu, Chenying, Chen, Jian, Suksaranjit, Promporn, Menda, Yusuf, Adhaduk, Mehul, Jayanna, Manju B., Scalzetti, Ernest, Ji, Jiansong, Wei, Tiemin, Feiglin, David, and Liu, Kan
- Subjects
SARCOIDOSIS ,FISHER exact test ,RECEIVER operating characteristic curves ,VENTRICULAR remodeling ,PROPORTIONAL hazards models ,STRESS echocardiography ,LEFT heart ventricle ,PREDICTIVE tests ,RETROSPECTIVE studies ,PROGNOSIS ,HEART physiology - Abstract
Background: The poor prognosis of cardiac sarcoidosis (CS) underscores the need for risk stratification.Purpose: To investigate the prognostic significance of ventricular/myocardial remodeling features in sarcoidosis.Study Type: Retrospective.Population: In all, 132 biopsy-proven sarcoidosis patients imaged from 2008 to 2018. The primary endpoint was a composite of cardiac mortality, new onset arrhythmias, hospitalization for heart failure, and device implantation.Field Strength/sequence: No field strength or sequence restrictions.Assessment: Global and regional ventricular/myocardial remodeling features were assessed by standard volumetric measurements and automated function imaging postprocessing analysis.Statistical Tests: Student's t-test or Mann-Whitney test (chi2 test or Fisher's exact test for categorical variables) were used for comparisons. Cox-proportional hazards regression model, univariate /multivariate analyses, and receiver operating characteristic were performed to relate clinical/lab data, imaging parameters to the endpoints.Results: Over a median follow-up of 40.7 (interquartile range 18.8-60.5) months, 41 (31.1%) patients developed adverse cardiac events. Abnormal left ventricular (LV) geometric remodeling alterations (measured by LV mass index and relative wall thickness) occurred 3.66-fold more frequently in patients with endpoints than patients without. The ratio of patients with endpoints increased as ventricular remodeling phenotype progressed. In patients with endpoints, regional myocardial wall thickness (RMWT) was significantly (P = 0.022) increased in six clustered LV segments located in the middle interventricular septum and basal/middle anterolateral walls. In all of the abnormal ventricular remodeling stages, patients with endpoints constantly had higher mean RMWT than those without. Among clinical, electrocardiographic, and imaging parameters, LV mass index (hazard ratio [HR] 1.010 95% confidence interval [CI] 1.002-1.018, P = 0.017) and mean RMWT (HR 3.482 95% CI 1.679-7.223, P = 0.001) were independently associated with endpoints. Sarcoidosis patients without this RMWT distribution pattern were significantly (P < 0.001) more likely to be free of the occurrence of subsequent cardiac events.Data Conclusion: Regional myocardial remodeling characteristics are associated with subsequent adverse cardiac events in sarcoidosis.Level Of Evidence: 3 TECHNICAL EFFICACY STAGE: 2 J. Magn. Reson. Imaging 2020;52:499-509. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer.
- Author
-
Fan, Yang, Ma, Xin, Li, Hongzhao, Gao, Yu, Huang, Qingbo, Zhang, Yu, Bao, Xu, Du, Qingshan, Luo, Guoxiong, Liu, Kan, Meng, Qingyu, Zhao, Chaofei, and Zhang, Xu
- Abstract
Although overall downregulation of microRNAs (miRNAs) is a general feature of clear-cell renal cell carcinoma (ccRCC), several miRNAs are consistently upregulated, among which miR-122 was markedly increased in ccRCC tissues. Our study aims to determine the functional importance and underlying mechanism of miR-122 in ccRCC metastasis. Here, we demonstrate that the expression of miR-122 increased in ccRCC tissues, and higher miR-122 expression was found in ccRCC tissues with metastatic disease than in those without metastasis. The increased miR-122 levels were associated with poor metastasis-free survival in ccRCC patients with localized disease. Dicer was validated as a direct functional target of miR-122. Overexpression of miR-122 promoted migration and invasion of ccRCC cells in vitro and metastatic behavior of ccRCC cells in vivo. Inhibition of miR-122 attenuated this metastatic phenotype in vitro. Importantly, miR-122 exerted its pro-metastatic properties in ccRCC cells by downregulating Dicer and its downstream effector, the miR-200 family, thereby inducing epithelial-mesenchymal transition (EMT). Our results suggest an important role of the miR-122/Dicer/miR-200s/EMT pathway in ccRCC metastasis. Furthermore, miR-122 may serve as a biomarker for discriminating ccRCC with metastatic potential. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
- Author
-
Tang, Lu, Li, Xintao, Wang, Baojun, Luo, Guoxiong, Gu, Liangyou, Chen, Luyao, Liu, Kan, Gao, Yu, and Zhang, Xu
- Subjects
PROSTATE cancer prognosis ,NEUTROPHILS ,LYMPHOCYTES ,BIOMARKERS ,SYSTEMATIC reviews - Abstract
Objective and Background: Increasing evidence suggests that inflammation plays an essential role in cancer development and progression. The inflammation marker neutrophil–lymphocyte ratio (NLR) is correlated with prognosis across a wide variety of tumor types, but its prognostic value in prostate cancer (PCa) remains controversial. In the present meta-analysis, the prognostic value of NLR in PCa patients is investigated. Methods: We performed a meta-analysis to determine the predictive value of NLR for overall survival (OS), recurrence-free survival (RFS), and clinical features in patients with PCa. We systematically searched PubMed, ISI Web of Science, and Embase for relevant studies published up to October 2015. Results: A total of 9418 patients from 18 studies were included in the meta-analysis. Elevated pretreatment NLR predicted poor OS (HR 1.628, 95% CI 1.410–1.879) and RFS (HR 1.357, 95% CI 1.126–1.636) in all patients with PCa. However, NLR was insignificantly associated with OS in the subgroup of patients with localized PCa (HR 1.439, 95% CI 0.753–2.75). Increased NLR was also significantly correlated with lymph node involvement (OR 1.616, 95% CI 1.167–2.239) but not with pathological stage (OR 0.827, 95% CI 0.637–1.074) or Gleason score (OR 0.761, 95% CI 0.555–1.044). Conclusions: The present meta-analysis indicated that NLR could predict the prognosis for patients with locally advanced or castration-resistant PCa. Patients with higher NLR are more likely to have poorer prognosis than those with lower NLR. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Prognostic and Predictive Values of Subcellular Localisation of RET in Renal Clear-Cell Carcinoma.
- Author
-
Wang, Lei, Zhang, Yu, Gao, Yu, Fan, Yang, Chen, Luyao, Liu, Kan, Meng, Qingyu, Zhao, Chaofei, and Ma, Xin
- Subjects
RENAL cell carcinoma ,PROTO-oncogenes ,SUBCELLULAR fractionation ,METASTASIS ,BIOMARKERS ,CANCER invasiveness ,PROGNOSIS - Abstract
Metastatic renal cell carcinoma (RCC) presents a poor prognosis and an unpredictable course. To date, no validated biomarkers can predict the outcome of RCC. Ongoing efforts are conducted to identify the molecular markers of RCC progression, as well as the targets for novel therapeutic approaches. RET is a tyrosine kinase receptor which has been investigated as a possible target in other cancers because it is involved in oncogenic activation. To evaluate the predictive and prognostic functions of RET in ccRCC, a tissue microarray study was conducted on 273 ccRCC patients. Results showed that both RET cytoplasmic and nuclear expression were independently associated with PFS and OS, and the combined RET cytoplasmic and nuclear statuses demonstrated that the ratio of high nuclear RET and cytoplasmic RET was the strongest predictor of both PFS and OS. The high cytoplasmic RET expression retained its independent poor prognostic value in targeted drug treated patients. The RET nuclear expression was associated with distant metastasis. Moreover, the RET nuclear expression was an independent predictor of ccRCC postoperative metastasis. In conclusion, RET may be useful in prognostication and can be used at initial diagnosis to identify patients with high potential to develop metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Wedge-shaped microfluidic chip for circulating tumor cells isolation and its clinical significance in gastric cancer.
- Author
-
Yang, Chaogang, Zhang, Nangang, Wang, Shuyi, Shi, Dongdong, Zhang, Chunxiao, Liu, Kan, and Xiong, Bin
- Subjects
LABS on a chip ,STOMACH cancer ,CANCER cells ,STOMACH cancer treatment ,IMMUNOCYTOCHEMISTRY ,PROGNOSIS - Abstract
Background: Circulating tumor cells (CTCs) have great potential in both basic research and clinical application for the managements of cancer. However, the complicated fabrication processes and expensive materials of the existing CTCs isolation devices, to a large extent, limit their clinical translation and CTCs' clinical value. Therefore, it remains to be urgently needed to develop a new platform for achieving CTCs detection with low-cost, mass-producible but high performance.Methods: In the present study, we introduced a novel wedge-shaped microfluidic chip (named CTC-ΔChip) fabricated by two pieces of glass through wet etching and thermal bonding technique for CTCs isolation, which achieved CTCs enrichment by different size without cell surface expression markers and CTCs identification with three-color immunocytochemistry method (CK+/CD45-/Nucleus+). We validated the feasibility of CTC-ΔChip for detecting CTCs from different types of solid tumor. Furthermore, we applied the newly-developed platform to investigate the clinical significance of CTCs in gastric cancer (GC).Results: Based on "label-free" characteristic, the capture efficiency of CTC-ΔChip can be as high as 93.7 ± 3.2% in DMEM and 91.0 ± 3.0% in whole blood sample under optimized conditions. Clinically, CTC-ΔChip exhibited the feasibility of detecting CTCs from different types of solid tumor, and it identified 7.30 ± 7.29 CTCs from 2 mL peripheral blood with a positive rate of 75% (30/40) in GC patients. Interestingly, we found that GC CTCs count was significantly correlated with multiple systemic inflammation indexes, including the lymphocyte count, platelet count, the level of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio. In addition, we also found that both the positivity rate and CTCs count were significantly associated with multiple clinicopathology parameters.Conclusions: Our novel CTC-ΔChip shows high performance for detecting CTCs from less volume of blood samples of cancer patients and important clinical significance in GC. Owing to the advantages of low-cost and mass-producible, CTC-ΔChip holds great potential of clinical application for cancer therapeutic guidance and prognostic monitoring in the future. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Prognostic role of bland thrombus in patients treated with resection of renal cell carcinoma with inferior vena cava tumor thrombus.
- Author
-
Wang, Hanfeng, Li, Xintao, Huang, Qingbo, Panic, Andrej, Shen, Donglai, Jia, Wangping, Zhang, Fan, Fan, Yang, Gao, Yu, Gu, Liangyou, Liu, Kan, Peng, Cheng, Chen, Changyu, Duan, Junyao, Chen, Jianwen, Wu, Shengpan, Xuan, Yundong, Wang, Chenfeng, Li, Hongzhao, and Ma, Xin
- Subjects
- *
VENA cava inferior , *THROMBOSIS , *OVERALL survival , *RENAL cell carcinoma , *PROPORTIONAL hazards models , *PROGRESSION-free survival - Abstract
Objectives: To assess the impact of the presence of bland thrombus (BT) on prognosis of patients treated with resection of renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVCTT).Materials and Methods: The medical records of a total of 145 consecutive postsurgical RCC patients with level I-IV IVCTT were reviewed from January 2008 to August 2018. Associations of BT with clinicopathological variables were estimated by chi-square test or Student's t-test. Kaplan-Meier method and multivariate Cox proportional hazard model were used. The eighth TNM staging system, "Spiess PE" model, University of California at Los Angeles Integrated Staging System and Stage, Size, Grade, and Necrosis (SSIGN) score were selected to assess whether BT could improve their predictive abilities.Results: BT was observed in 34 (23.4%) patients and was significantly associated with increased levels of IVCTT (P = 0.004) and invasion of IVC wall (P = 0.030). Multivariable Cox analyses revealed that tumor grade, T stage, M stage, tumor thrombus consistency and BT were independent risk factors for both progression-free survival and overall survival. The concordance indexes ranged from a low of 0.652 in TNM to a high of 0.731 in SSIGN, and integrating BT into each base model led to an increased predictive accuracies of 6.2% for TNM (P = 0.025), 4.0% for "Spiess PE" model (P = 0.069), 2.1% for University of California at Los Angeles Integrated Staging System (P = 0.149) and 1.2% for SSIGN (P = 0.290), respectively.Conclusions: Presence of BT was independently associated with survival in postsurgical patients with RCC-IVCTT. Routine consideration of BT as an adjunct to TNM staging system may be suggested. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.